High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus-Reference-Cited by-同舟云学术

High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus

Published:2023-02-16 Issue:2 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Jarrett Ryan T.¹^ORCID,van der Heijden Yuri²³⁴,Shotwell Matthew S.⁵,Chihota Violet¹²⁴,Marzinke Mark A.⁶^ORCID,Chaisson Richard E.⁷⁸,Dooley Kelly E.⁶⁷^ORCID,Churchyard Gavin J.¹⁴⁹

Affiliation:

1. Institute for Global Health, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

2. Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

3. Vanderbilt Tuberculosis Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

4. The Aurum Institute, Johannesburg, South Africa

5. Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

6. Departments of Pathology and Medicine (Clinical Pharmacology), Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

7. Department of Medicine Infectious Diseases, Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland, USA

8. Department of International Health and Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA

9. School of Public Health, University of Witwatersrand, Johannesburg, South Africa

Abstract

Isoniazid pharmacokinetics are not yet well-described during once weekly, high-dose administrations with rifapentine (3HP) for latent tuberculosis infection (LTBI). Fewer data describe 3HP with dolutegravir-based antiretroviral therapy for the treatment of human immunodeficiency virus (HIV).

Funder

UNITAID

HHS | NIH | Fogarty International Center

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01297-22

Reference39 articles.

1. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling

2. World Health Organization. 2018. Latent tuberculosis infection: updated and conosolidated guidelines for programmatic management.

3. Are We There Yet? Short-Course Regimens in TB and HIV: From Prevention to Treatment of Latent to XDR TB

4. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection;Centers for Disease Control and Prevention (CDC);MMWR Morbidity and Mortality Wkly Report,2011

5. Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complexities of rifamycin use in persons with HIV infection;AIDS;2023-06-01

2. Parametric population pharmacokinetics of isoniazid: a systematic review;Expert Review of Clinical Pharmacology;2023-04-03